MG98 in Treating Patients With Advanced Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically proven advanced solid tumor unresponsive to existing therapy or for which no curative therapy exists
• Evidence of disease in addition to tumor marker elevation
• CNS metastases allowed, if adequately treated and symptoms controlled for greater than 4 months
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2
• Life expectancy:
• At least 12 weeks
• Hematopoietic:
• Absolute granulocyte count at least 1,500/mm3
• Platelet count at least 100,000/mm3
• PTT normal
• Hepatic:
• Bilirubin no greater than 1.25 times upper limit of normal (ULN)
• SGOT or SGPT no greater than 3 times ULN (4 times ULN for liver metastases)
• Renal:
• Creatinine no greater than 1.25 times ULN
• Proteinuria less than 2+ (no greater than 500 mg in a 24 hour urinalysis)
• Other:
• No active infection
• No other serious systemic disease
• No known hypersensitivity to oligodeoxynucleotides
• Adequate venous access
• No known condition (e.g., psychological, geographical) that would prevent compliance
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after the study
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No concurrent colony stimulating factors unless evidence of neutropenic infection
• Chemotherapy:
• No more than 3 prior chemotherapy regimens
• At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered
• At least 1 year since prior high dose chemotherapy with bone marrow or stem cell support
• No concurrent chemotherapy
• Endocrine therapy:
• Prior hormonal therapy allowed
• No concurrent hormonal therapy
• Radiotherapy:
• At least 4 weeks since prior radiotherapy and recovered
• Concurrent palliative radiotherapy allowed
• Surgery:
• At least 2 weeks since prior major surgery
• Other:
• At least 3 weeks since prior investigational drug therapy
• No other concurrent investigational drug or anticancer therapy
• No concurrent coumadin or heparin therapy